In the past 20 years the application of mammography, cytological examinations and echography has facilitated earlier diagnosis of breast cancer. Simultaneously, less mutilating surgery and hormonal and cytotoxic therapy were introduced. These treatments have proved their efficacy in academic settings (Early Breast Cancer Trialist's Collaborative Group, 1992) . Nevertheless, there are only few reports on improved survival rates in a general population (Hakulinen et al., 1981; Adami et al., 1986; Levi et al., 1992;  Carstensen et al., 1993; Miller et al., 1993) . Moreover, follow-up of more than 10 years is rare (Adami et al., 1986) , and differentiation according to stage (Hakulinen et al., 1981; Carstensen et al., 1993; Miller et al., 1993) or between followup intervals is seldom made. We investigated trends in relative survival rates of breast cancer in women diagnosed between 1970 and 1984 in south-eastern Netherlands according to stage and interval of follow-up.
Subets and method
The study comprised female patients with a first primary invasive breast cancer diagnosed between 1970 and 1984 in south-eastern Netherlands, with follow-up until 1991. Data came from the Eindhoven Cancer Registry, which was founded in 1955 and has been part of the Comprehensive Cancer Centre South since 1983 (Coebergh et al., 1992) . The data were derived from the patients' files in the commumity hospitals, from copies of the pathologists' records and from the regional Radiotherapy Institute. The registry covered a densely populated area in south-eastern Netherlands with about 900,000 inhabitants since 1970. Incidence rates could be estimated from 1960 onward in this population (Nab et al., 1993 (Hakulinen, 1982) . Actuarial survival curves were computed (Berkson & Gage, 1950) according to age group, tumour stage and period of diagnosis (1970-74, 1975-79, 1980-84) . The excess risk of death due to breast cancer was modelled using a program of the Finnish Cancer Registry (Hakulinen & Tenkanen, 1987) . In this model the annual excess mortality is allowed to depend simultaneously on age, stage and period of diagnosis. The excess mortality is obtained by taking the difference between the observed mortality and the expected mortality. The latter is determined by the age of the patients and the calendar period. The excess mortality presumably reflects deaths in which breast cancer is the cause. In this analysis method it is assumed that the various factors have a proportional effect on the excess death rate. As this assumption appeared to be violated when the total follow-up interval after diagnosis was considered, separate analyses were performed for each 5 year interval. In the analyses all variables were taken to be categorical in the first instance. Because the factor of primary interest, i.e. diagnostic period, had estimated effects which were roughly linear with increasing period, it was introduced in the models using the numerical codes 0, 1 and 2 for the subsequent periods of diagnosis, thereby allowing tests for linear trend to be performed. We investigated whether the diagnostic period effect depended on stage or age of patients at diagnosis by incorporating interaction terms in the models. In the final model death rate ratios were expressed as the ratio of two death rates in two groups of patients diagnosed in two consecutive 5 year periods, with adjustment for age and stage, as an indicator of the change in prognosis over time. Other statistical methods are indicated in the text. P-values given are two-sided; 5% was considered the limit of significance. Br. J. Cancer (1994), 70, 285-288 (Table I) .
Observed survival rates at 5, 10 and 20 years were 63%, 44% and 30%, respectively, and the corresponding relative survival percentages were 69%, 55% and 50%. The 5 year relative survival rates improved steadily from 61% for patients diagnosed in Years after diagnosis significantly worse prognosis. Stage at diagnosis was an important independent prognostic factor, but its effect diminished during the follow-up (Table II) . Period of diagnosis was also a significant and independent prognostic factor in the first and the second 5 years of follow-up, but not statistically significant thereafter. The estimated improvement in relative survival compared with patients diagnosed 5 years earlier was 30% for the first 5 years of follow-up (P<0.001), 20% in the second 5 years of follow-up (P = 0.02) and 40% for the third 5 years (P = 0.07). This improvement according to diagnostic period did not significantly differ between the three separate stage groups, and was apparent in all age categories. Among the patients with unknown stage, ageadjusted relative survival improved by 10% (P>0.1). Between 1970 and 1984 the 311 patients (7%) with distant disease at diagnosis had a median observed survival of 1.2 years. Of these patients, 37% survived 2 years, and only 14% for more than 5 years. Relative survival rates, after adjustment for age, in this group of patients did not change significantly (Table II) .
Discussion
The prognosis of breast cancer patients with non-metastatic disease diagnosed between 1970 and 1984 in south-eastern Netherlands improved markedly in all age groups and during the whole follow-up interval of 15 years. The incmreased survival rates, together with earlier diagnosis, concur with the earlier reported marked increase in breast cancer incidence and stable mortality in this region (Nab et al., 1993) .
Explanations for this improvement may include better therapy, earlier diagnosis and inclusion of less aggressive cancer types, while the general improvement of life expectancy has been corrected by using relative survival. More effective treatments include hormonal and cytotoxic therapy, of which the latter in particular was increasingly administered as adjuvant, and also as secondary treatment. Cinical trials (Early Breast Cancer Trialist's Collaborative Group, 1992) This table gives the results from the final model in which only patients with stages I-III were included. For patients with unknown stage the age-adjusted excess death rate ratios (95% CI) according to period of diagnosis were 0.9 (0.8-1.2), 0.9 (0.7-1.5) and 0.9 (0.3-3.4) for the three follow-up intervals. For patients with distant disease at diagnosis the age-adjusted excess death rate ratio (95% CI) was 1.0 (0.9-1.1) for the first 5 years of follow-up. aReferene category. received adjuvant chemo-or hormonal therapy. In our series (besides occasional use in stage I patients) the percentage of patients with stage II or III disease receiving adjuvant chemo-or hormonal therapy increased from 2% and 10%, respectively, in 1970-74 to 22% and 27%, respectively, in 1980-84. However, when multivariate analysis was repeated while excluding all patients who received adjuvant chemo-or hormonal therapy, the estimated reductions in excess death rates thus found were very similar to those shown in Table   II (Fisher et al., 1989; Clark et al., 1992) .
The reported overall relative survival rates are similar to survival rates in some other European cancer registries (Sant et al.. 1991; Carstensen et al., 1993) Moreover, some questions remain about the validity of this considerable improvement in survival rates. Although an adjustment was made for the increase in earlier stage at diagnosis over time, using multivariate analysis, earlier detection may still have had a small impact on stage-specific outcome, since within the stage groups a trend towards earlier detection is also likely (Black & Welch, 1993) . Furthermore, in later years, an increasing number of patients may have been allocated to higher stages owing to introduction of more extensive staging procedures, particularly axillary nodal clearance (Danforth et al., 1986) . This may also have contributed to a slightly more favourable outcome in all stages (Feinstein et al., 1985) . As relative survival also improved in the patients with unknown stage at diagnosis, bias caused by this group of patients is probably small.
It seems justified to conclude that the improvement in prognosis in short-term as well as in long-term survival is real, and is in accordance with the diverging trends in incidence and mortality in this region. This improvement in prognosis cannot be attributed to a decrease in other causes of death. However, detection of less malignant cancer, or a change in the natural history of the disease in this period, cannot be ruled out (Joensuu & Toikkanen, 1991) .
